Expertise in
7
conditions

Frederic Kridelka

CHU Liège
Liege, WAL, BE 
Expertise in
7
conditions
CHU Liège
Liege, WAL, BE 
OverviewLocationsClinical Research

Overview

Frederic Kridelka practices in Liege, Belgium. Mr. Kridelka is highly rated in 7 conditions, according to our data. His top areas of expertise are Cervical Cancer, Gestational Trophoblastic Disease, Endometrial Cancer, Hysterectomy, and Lymphadenectomy.

His clinical research consists of co-authoring 94 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

CHU Liège
Liege, WAL, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Atezolizumab in Combination With Bevacizumab and Chemotherapy Versus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer - a Randomized Phase III Trial
Atezolizumab in Combination With Bevacizumab and Chemotherapy Versus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer - a Randomized Phase III Trial
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug
Study Drugs: Bevacizumab, Atezolizumab, Chemotherapy
Study Phase: Phase 3
A Phase III Randomized, Double-blinded Trial of Platinum-based Chemotherapy With or Without Atezolizumab Followed by Niraparib Maintenance With or Without Atezolizumab in Patients With Recurrent Ovarian, Tubal or Peritoneal Cancer and Platinum Treatment-free Interval (TFIp) >6 Months
A Phase III Randomized, Double-blinded Trial of Platinum-based Chemotherapy With or Without Atezolizumab Followed by Niraparib Maintenance With or Without Atezolizumab in Patients With Recurrent Ovarian, Tubal or Peritoneal Cancer and Platinum Treatment-free Interval (TFIp) >6 Months
Enrollment Status: Completed
Publish Date: August 30, 2024
Intervention Type: Drug
Study Drugs: Carboplatin, Paclitaxel, Niraparib, Gemcitabine, Pegylated liposomal doxorubicin, Atezolizumab
Study Phase: Phase 3
Phase IB-II, Open Label, Multicenter Feasibility Study of Pazopanib in Combination With Paclitaxel and Carboplatin in Patients With Platinum-Refractory/Resistant Ovarian, Fallopian Tube or Peritoneal Carcinoma
Phase IB-II, Open Label, Multicenter Feasibility Study of Pazopanib in Combination With Paclitaxel and Carboplatin in Patients With Platinum-Refractory/Resistant Ovarian, Fallopian Tube or Peritoneal Carcinoma
Enrollment Status: Completed
Publish Date: December 11, 2023
Intervention Type: Other, Drug
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

94 Total Publications

Adaptations and constraints : obstetrical complications in the light of phylogenesis
Adaptations and constraints : obstetrical complications in the light of phylogenesis
Journal: Revue medicale de Liege
Published: April 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kridelka's expertise for a condition
ConditionClose
    View All 20 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile